{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T07:02:43Z","timestamp":1792134163257,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T00:00:00Z","timestamp":1639180800000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.ejca.2020.11.009","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T18:13:37Z","timestamp":1607710417000},"page":"9-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer"],"prefix":"10.1016","volume":"144","author":[{"given":"Raphael","family":"Colle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3440-9635","authenticated-orcid":false,"given":"Anna","family":"Radzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9602-5162","authenticated-orcid":false,"given":"Romain","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pellat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lopez-Tabada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-7950","authenticated-orcid":false,"given":"Marine","family":"Cachanado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Svrcek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Menu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.11.009_bib1","first-page":"11","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability\u2013high\/mismatch repair\u2013deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le","year":"2019","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2020.11.009_bib2","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.11.009_bib3","first-page":"3514","article-title":"KEYNOTE-164: pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer","volume":"36","author":"Le","year":"2018","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2020.11.009_bib4","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib5","first-page":"635","article-title":"Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high\/mismatch repair-deficient (MSI-H\/dMMR) metastatic colorectal cancer (mCRC): long-term follow-up","volume":"37","author":"Overman","year":"2019","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2020.11.009_bib6","first-page":"519","article-title":"Nivolumab in patients with DNA mismatch repair deficient\/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142","volume":"35","author":"Overman","year":"2017","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2020.11.009_bib7","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high\/mismatch repair deficient metastatic colorectal cancer: the phase 3 KEYNOTE-177 Study","volume":"38","author":"Andre","year":"2020","journal-title":"J Clin Orthod"},{"key":"10.1016\/j.ejca.2020.11.009_bib9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib10","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib11","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.11.009_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40425-017-0301-y","article-title":"Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials","volume":"5","author":"Groisberg","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2020.11.009_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/CJI.0000000000000222","article-title":"Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy","volume":"41","author":"Parseghian","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2020.11.009_bib14","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/1078-0432.CCR-18-0793","article-title":"Long-term survival in patients responding to anti-PD-1\/PD-L1 therapy and disease outcome upon treatment discontinuation","volume":"25","author":"Gauci","year":"2019","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejca.2020.11.009_bib16","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2020.11.009_bib17","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jtho.2018.12.011","article-title":"Pseudoprogression in non-small cell lung cancer upon immunotherapy: few drops in the ocean?","volume":"14","author":"Ferrara","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib18","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jtho.2018.10.167","article-title":"Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy","volume":"14","author":"Fujimoto","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib19","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jtho.2018.04.010","article-title":"Radiologic pseudoprogression during anti-PD-1 therapy for advanced non-small cell lung cancer","volume":"13","author":"Katz","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib20","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.11.009_bib21","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/cam4.2797","article-title":"Evidence of pseudoprogression in patients treated with PD1\/PDL1 antibodies across tumor types","volume":"9","author":"Martin-Romano","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2020.11.009_bib22","doi-asserted-by":"crossref","first-page":"57889","DOI":"10.18632\/oncotarget.18361","article-title":"Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2020.11.009_bib23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.11.009_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djx136","article-title":"The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors","volume":"110","author":"Marisa","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.11.009_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Canc Discov"},{"key":"10.1016\/j.ejca.2020.11.009_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1001\/jamaoncol.2017.5332","article-title":"Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti-programmed cell death 1 antibodies","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib27","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2217\/fon-2019-0183","article-title":"Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy","volume":"15","author":"Failing","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2020.11.009_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40259-020-00425-y","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.ejca.2020.11.009_bib29","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1038\/s41467-019-11007-0","article-title":"Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastoma","volume":"10","author":"Elshafeey","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2020.11.009_bib30","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin Canc Res"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920313320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:35Z","timestamp":1760732975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920313320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":30,"alternative-id":["S0959804920313320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.009","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}